Abstracts tagged "giant cell arteritis"

Abstract Number: 801 • 2014 ACR/ARHP Annual Meeting
Venothromboembolism in Large Vessel Vasculitis
Sankalp V. Bhavsar¹, Nader A. Khalidi², Simon Carette³, David Cuthbertson⁴, Peter C. Grayson⁵, Gary S. Hoffman⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol McAlear⁹, Larry Moreland¹⁰, Paul A. Monach¹¹, Christian Pagnoux³, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Department of Biostatistics, University of South Florida, Tampa, FL, ⁵NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, ¹¹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹²Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Venous thromboembolic disease (VTE) is a recognized characteristic of various systemic vasculitides, particularly small-vessel vasculitis. However, there are no reports describing the frequency of…
Abstract Number: 1688 • 2013 ACR/ARHP Annual Meeting
Does The Treatment With Anti-Coagulants and Anti-Platelets Protect Giant Cell Arteritis Patients From Visual Manifestations?
Andreas P. Diamantopoulos, Helene Hetland, Glenn Haugeberg, Dag Magnar Soldal and Geirmund Myklebust, Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway
Background/Purpose: Visual manifestations such as diplopia, amaurosis fugax or blindness occur in up to half of the giant cell arteritis (GCA) patients. Some studies have…
Abstract Number: 1665 • 2013 ACR/ARHP Annual Meeting
B Cells Revisited In Giant Cell Arteritis
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst², Caroline Roozendaal³, Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is a primary vasculitis affecting large to medium-sized arteries. Ample evidence suggests that dendritic cells, T cells and monocytes/macrophages contribute…
Abstract Number: 1666 • 2013 ACR/ARHP Annual Meeting
Negative Temporal Artery Biopsies: Pathologic Findings Of Patients With Biopsy-Negative Giant Cell Arteritis Compared To Those Of Patients Without Arteritis
Francesco Muratore¹, Alberto Lo Gullo¹, Alberto Cavazza², Giuseppe Germanò¹, Luigi Boiardi¹ and Carlo Salvarani³, ¹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). A negative TAB does…
Abstract Number: 1677 • 2013 ACR/ARHP Annual Meeting
May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?
Rosaria Talarico¹, Chiara Stagnaro², Claudia Ferrari³, Anna d'Ascanio⁴, Chiari Tani², Chiara Baldini², Marta Mosca³ and Stefano Bombardieri², ¹Rheumatology Unit, Pisa, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy
Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that affect large and medium-sized arterial vessels. Growing data shown that…
Abstract Number: 1678 • 2013 ACR/ARHP Annual Meeting
How Similar Are Extracranial Giant Cell Arteritis and Takayasu Arteritis?
Tanaz A. Kermani¹, Cynthia S. Crowson², Francesco Muratore³, Jean Schmidt⁴, Eric L. Matteson⁵ and Kenneth J. Warrington⁶, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Internal Medicine and RECIF, CHU Nord, Amiens, France, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: The clinical and radiographic features of giant cell arteritis (GCA) with extracranial (large-vessel) involvement can be similar to those of Takayasu arteritis (TAK)…
Abstract Number: 1664 • 2013 ACR/ARHP Annual Meeting
Lower Tissue Expression Of IL 6 In Patients With Giant Cell Arteritis Presenting With a Cranial Ischaemic Compication
Lorraine O'Neill¹, Jennifer McCormick², Danielle Molloy¹, Douglas J. Veale¹, Conor Murphy³, Geraldine M. McCarthy⁴, Ursula Fearon² and Eamonn S. Molloy¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland
Background/Purpose: Giant Cell Arteritis (GCA) is a granulomatous systemic vasculitis with a prediliction for the aorta and it’s extracranial branches. The majority of the morbidity…
Abstract Number: 892 • 2013 ACR/ARHP Annual Meeting
The Functional PTPN22 Variant R620W Is Strongly Associated With Giant Cell Artetitis Predisposition
F. David Carmona¹, Sarah L. Mackie², Aurora Serrano³, Ana Marquez⁴, Roser Solans⁵, Jose A. Miranda-Filloy⁶, Jose Hernández-Rodríguez⁷, Maria C. Cid⁸, Santos Castañeda⁹, Inmaculada C. Morado¹⁰, Javier Narvaez¹¹, Ricardo Blanco¹², Bernardo Sopeña¹³, M. Jesus García-Villanueva¹⁴, Jordi Monfort¹⁵, Norberto Ortego-Centeno¹⁶, Ainhoa Unzurrunzaga¹⁷, Begoña Marí-Alfonso¹⁸, Julio Sánchez-Martín¹⁹, Eugenio de Miguel²⁰, Cesar Magro²¹, Enrique Raya²², Niko Braun²³, Joerg Latus²⁴, Øyvind Molberg²⁵, Benedicte A. Lie²⁶, Frank Moosig²⁷, Torsten Witte²⁸, Ann W. Morgan², Miguel A. González-Gay²⁹ and Javier Martin³, ¹Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, ⁴Instituto de Parasitología y Biomedicina 'López-Neyra' (IPBLN-CSIC), Granada, Spain, ⁵Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁸Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ¹³Thrombosis and Vasculitis Unit-Internal Medicine, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain, ¹⁴Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Reumatologia, Hospital del Mar, Barcelona, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁷Internal Medicine, Hospital de Galdakano, Vizcaya, Spain, ¹⁸Internal Medicine, Corporació Sanitaria Parc Taulí, Instituto Universitario Parc Taulí, UAB, Sabadell, Spain, ¹⁹Rheumatology,, Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ²¹Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ²²Rheumatology, University Hospital San Cecilio, Granada, Spain, ²³Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ²⁴Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ²⁵Oslo University Hospital, Oslo, Norway, ²⁶Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ²⁷Department of Clinical Immunology and Rheumatology, University of Luebeck, Bad Bramstedt, Germany, ²⁸Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ²⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: The PTPN22/CSK signaling represents one of the common susceptibility pathways in autoimmunity. Considering that the genetic basis of giant cell arteritis (GCA), an autoimmune…
Abstract Number: 896 • 2013 ACR/ARHP Annual Meeting
Increased Rho Kinase (ROCK) Activity In Temporal Artery Biopsies From Patients With Giant Cell Arteritis (GCA)
Lindsay Lally¹, Navneet Narula², Alessandra B. Pernis³, Wei-Ti Huang⁴, Uzunma Udeh¹ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pathology, Weill Cornell Medical College, New York, NY, ³Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ⁴Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: ROCKs are implicated in the pathogenesis of many vascular diseases. ROCK activation is associated with Th17 differentiation and production of Th17-associated cytokines, IL-17 and…
Abstract Number: 2667 • 2013 ACR/ARHP Annual Meeting
Fast-Track Pathway In Giant Cell Arteritis: A Cost-Effectivenss Analysis
Katerina Achilleos¹, Pravin Patil¹, Win Win Maw¹, Laura Bown², David Halsall², Charles Dobson², Christian Dejaco³, Frances Borg¹, Sunil Gupta⁴ and Bhaskar Dasgupta¹, ¹Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ²Department Of Health, National Health Service England, Leeds, United Kingdom, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Castlepoint and Rochford, Clinical Commissioning Group, Southend-on-sea, United Kingdom
Background/Purpose: With incidence of 2.2 per 10,000 patient years, it is estimated that 12,000 new cases of Giant Cell Arteritis (GCA) are diagnosed every…
Abstract Number: 1861 • 2013 ACR/ARHP Annual Meeting
Neurotrophins Are Involved In Vascular Remodeling Of Giant Cell Arteritis
Kim Heang Ly^1,2, Alexis Régent³, Elsa Molina⁴, Sofiane Saada⁴, Philippe Sindou⁴, Claire Le Jeunne⁵, Antoine Brezin⁶, Veronique witko-Sarsat³, Philippe Bertin⁷, Francois Labrousse⁸, Pierre-Yves Robert⁹, Anne-Laure Fauchais¹⁰, Elisabeth Vidal¹⁰, Luc Mouthon¹¹ and Marie-Odile Jauberteau⁴, ¹CHU Dupuytren, Limoges, Limoges, France, ²Immunology Laboratory, EA3842, Limoges Medical school, Limoges, France, ³Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, ⁴Immunology Laboratory, EA 3842, Limoges Medical School, Limoges, France, ⁵Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ⁶Service d’ophtalmologie, hôpital Cochin, AP-HP, Paris, France, ⁷Hôpital Dupuytren, Limoges, France, ⁸Department of Pathology, Limoges University Hospital, Limoges, France, ⁹Departement of Ophthalmology, Limoges University Hospital, Limoges, France, ¹⁰Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessels vasculitis. Hhistopathological findings show cellular infiltrates, internal elastic lumina disruption and intimal hyperplasia leading to luminal stenosis.…
Abstract Number: 2568 • 2012 ACR/ARHP Annual Meeting
The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Diane Lacaille², Eric C. Sayre³, Jacek A. Kopec³ and Hyon Choi⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Arthritis Research Centre of Canada/University of British Columbia, Boston, MA
Background/Purpose: A recent hospital-based study has suggested an 8 fold increased risk of pulmonary embolism (PE) in individuals with polymyalgia rheumatica in the year following…
Abstract Number: 2390 • 2012 ACR/ARHP Annual Meeting
Color Doppler Ultrasonography an Alternative to CT/MR Angiography for Identifying Large Vessel Involvement in Giant Cell Arteritis?
Andreas P. Diamantopoulos¹, Glenn Haugeberg¹ and Geirmund Myklebust², ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Hospital of Southern Norway, Kristiansand, Norway
Background/Purpose: Large vessel involvement has been reported to be present in 20-50% of patients with giant cell arteritis (GCA). Computed tomography (CT) and magnetic resonance…
Abstract Number: 2350 • 2012 ACR/ARHP Annual Meeting
Similarities Exceeds Differences in the Pattern of Joint and Vascular Positron Emission/Computed Tomography Uptake in Polymyalgia Rheumatica and Giant Cell Arteritis
Dario Camellino¹, Silvia Morbelli², Francesco Paparo³, Michela Massollo², Gianmario Sambuceti⁴ and Marco A. Cimmino⁵, ¹Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²Dipartimento Medicina Interna, Medicina Nucleare, Genova, Italy, ³Radiology Unit, E.O. Ospedali Galliera, Genoa, Italy, ⁴Dipartimento di Medicina Interna, Medicina Nucleare, Genova, Italy, ⁵Department of Internal Medicine, Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two frequent overlapping diseases. The purpose of this work is to examine the relationship between…
Abstract Number: 2353 • 2012 ACR/ARHP Annual Meeting
TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis
Peadar Rooney¹, Danielle Molloy¹, Jennifer McCormick², Mary Connolly¹, Sinead M. Miggin³, Ashwini Maratha³, Douglas J. Veale⁴, Conor Murphy⁵, Eamonn Molloy⁶ and Ursula Fearon⁷, ¹Rheumatology, Dublin Academic Medical Centre, Dublin, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Biology, Immune Signalling Laboratory, Maynooth, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁷Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis of this disease is characterised by disregulated angiogenesis and inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].